Pan-Cancer Analysis of the Tumorigenic Effect and Prognostic Diagnostic Value of FAM111B in Human Carcinomas

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Chen W, Li Y, Guo L, Zhang C, Tang S. Long non-coding RNA FTX predicts a poor prognosis of human cancers: a meta-analysis. Biosci Rep. 2021;41(1). doi:10.1042/BSR20203995
   Web of Science ®Google Scholar
• Roshani M, Baniebrahimi G, Mousavi M, et al. Exosomal long non-coding RNAs: novel molecules in gastrointestinal cancers’ progression and diagnosis. Front Oncol. 2022;12:1014949. doi:10.3389/fonc.2022.1014949
   PubMed Web of Science ®Google Scholar
• Mercier S, Kury S, Shaboodien G, et al. Mutations in FAM111B cause hereditary fibrosing poikiloderma with tendon contracture, myopathy, and pulmonary fibrosis. Am J Hum Genet. 2013;93(6):1100–1107. doi:10.1016/j.ajhg.2013.10.013
   PubMed Web of Science ®Google Scholar
• Wu Y, Wen L, Wang P, Wang X, Zhang G. FAM111BCase Report: diverse phenotypes of congenital poikiloderma associated with mutations in codon 628: a case report and literature review. Front Genet. 2022;13:926451. doi:10.3389/fgene.2022.926451
   PubMed Web of Science ®Google Scholar
• Mercier S, Kury S, Nahon S, Salort-Campana E, Barbarot S, Bezieau S. FAM111B mutation is associated with pancreatic cancer predisposition. Pancreas. 2019;48(5):e41–e42. doi:10.1097/MPA.0000000000001303
   PubMed Web of Science ®Google Scholar
• Welter A, Machida Y. Functions and evolution of FAM111 serine proteases. Front Mol Biosci. 2022;9:1081166. doi:10.3389/fmolb.2022.1081166
   PubMed Web of Science ®Google Scholar
• Sun H, Liu K, Huang J, et al. FAM111B, a direct target of p53, promotes the malignant process of lung adenocarcinoma. Onco Targets Ther. 2019;12:2829–2842. doi:10.2147/OTT.S190934
   PubMed Web of Science ®Google Scholar
• Kawasaki K, Nojima S, Hijiki S, et al. FAM111B enhances proliferation of KRAS-driven lung adenocarcinoma by degrading p16. Cancer Sci. 2020;111(7):2635–2646. doi:10.1111/cas.14483
   PubMed Web of Science ®Google Scholar
• Li W, Hu S, Han Z, Jiang X. YY1-induced transcriptional activation of FAM111B contributes to the malignancy of breast cancer. Clin Breast Cancer. 2022;22(4):e417–e25. doi:10.1016/j.clbc.2021.10.008
   PubMed Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–678. doi:10.1038/s41587-020-0546-8
   PubMed Web of Science ®Google Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–W14. doi:10.1093/nar/gkaa407
   PubMed Web of Science ®Google Scholar
• Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–W60. doi:10.1093/nar/gkz430
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.002
   PubMed Web of Science ®Google Scholar
• Dong ZB, Wu HM, He YC, et al. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1. Cell Death Dis. 2022;13(1):35. doi:10.1038/s41419-021-04491-0
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. doi:10.1126/scisignal.2004088
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362–D68. doi:10.1093/nar/gkw937
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523. doi:10.1038/s41467-019-09234-6
   PubMed Web of Science ®Google Scholar
• Oughtred R, Rust J, Chang C, et al. The BioGRID database: a comprehensive biomedical resource of curated protein, genetic, and chemical interactions. Protein Sci. 2021;30(1):187–200. doi:10.1002/pro.3978
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–489. doi:10.1038/nature10673
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Mimura K, Ashizawa M, et al. Characterization of tumor-infiltrating immune cells in relation to microbiota in colorectal cancers. Cancer Immunol Immunother. 2020;69(1):23–32. doi:10.1007/s00262-019-02433-6
   PubMed Web of Science ®Google Scholar
• Sahai E, Astsaturov I, Cukierman E, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nature reviews. Cancer. 2020;20(3):174–186. doi:10.1038/s41568-019-0238-1
   PubMed Web of Science ®Google Scholar
• Desbois M, Wang Y. Cancer-associated fibroblasts: key players in shaping the tumor immune microenvironment. Immunol Rev. 2021;302(1):241–258. doi:10.1111/imr.12982
   PubMed Web of Science ®Google Scholar
• Chan T, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56. doi:10.1093/annonc/mdy495
   PubMed Web of Science ®Google Scholar
• Luchini C, Bibeau F, Ligtenberg M, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30(8):1232–1243. doi:10.1093/annonc/mdz116
   PubMed Web of Science ®Google Scholar
• Flex E, Martinelli S, Van Dijck A, et al. Aberrant function of the C-terminal tail of HIST1H1E accelerates cellular senescence and causes premature aging. Am J Hum Genet. 2019;105(3):493–508. doi:10.1016/j.ajhg.2019.07.007
   PubMed Web of Science ®Google Scholar
• Yang L, Zhang Q, Niu T, Liu H. SET levels contribute to cohesion fatigue. Mol Biol Cell. 2021;32(13):1256–1266. doi:10.1091/mbc.E20-12-0778
   PubMed Web of Science ®Google Scholar
• Ciolfi A, Aref-Eshghi E, Pizzi S, et al. Frameshift mutations at the C-terminus of HIST1H1E result in a specific DNA hypomethylation signature. Clin Epigenetics. 2020;12(1):1–11. doi:10.1186/s13148-019-0804-0
   Web of Science ®Google Scholar
• Rosati A, Graziano V, De Laurenzi V, Pascale M, Turco M. BAG3: a multifaceted protein that regulates major cell pathways. Cell Death Dis. 2011;2(4):e141–e41. doi:10.1038/cddis.2011.24
   PubMedGoogle Scholar
• Arowolo A, Rhoda C, Khumalo N. Mutations within the putative protease domain of the human FAM111B gene may predict disease severity and poor prognosis: a review of POIKTMP cases. Exp Dermatol. 2022;31(5):648–654. doi:10.1111/exd.14537
   PubMed Web of Science ®Google Scholar
• Pan X, Zheng S. Clinical and genetic characteristics of nevus of Ota with choroidal melanoma in Chinese. Ophthalmic Genet. 2019;40(4):338–341. doi:10.1080/13816810.2019.1650073
   PubMed Web of Science ®Google Scholar
• Goussot R, Prasad M, Stoetzel C, Lenormand C, Dollfus H, Lipsker D. Expanding phenotype of hereditary fibrosing poikiloderma with tendon contractures, myopathy, and pulmonary fibrosis caused by FAM111B mutations: report of an additional family raising the question of cancer predisposition and a short review of early-onset poikiloderma. JAAD Case Rep. 2017;3(2):143–150. doi:10.1016/j.jdcr.2017.01.002
   PubMedGoogle Scholar
• Pe’er D, Ogawa S, Elhanani O, Keren L, Oliver TG, Wedge D. Tumor heterogeneity. Cancer Cell. 2021;39(8):1015–1017. doi:10.1016/j.ccell.2021.07.009
   PubMed Web of Science ®Google Scholar
• Rhoda C, Sunda F, Kidzeru E, Khumalo NP, Arowolo A. FAM111B dysregulation promotes malignancy in fibrosarcoma and POIKTMP and a low-cost method for its mutation screening. Cancer Treat Res Commun. 2023;34:100679. doi:10.1016/j.ctarc.2022.100679
   PubMedGoogle Scholar
• Dereure O. Poïkilodermie fibrosante héréditaire avec contractures, myopathie et fibrose pulmonaire: responsabilités de mutations de FAM111B [Hereditary fibrosing poikiloderma with contractures, myopathy and pulmonary fibrosis: The role of mutations in FAM111B]. Ann Dermatol Venereol. 2014;141(6–7):478–479. French. doi:10.1016/j.annder.2014.03.017
   PubMed Web of Science ®Google Scholar
• Hoffmann S, Pentakota S, Mund A, et al. FAM111 protease activity undermines cellular fitness and is amplified by gain-of-function mutations in human disease. EMBO Rep. 2020;21(10):e50662. doi:10.15252/embr.202050662
   PubMed Web of Science ®Google Scholar